contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-orexos-q3-2025-interim-report

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Orexo

Uppsala, Sweden – October 14, 2025 – As previously communicated Orexo will announce the Interim Report for the third quarter of 2025 on October 23 at 8 am CEST.At 2 pm the same day, analysts...

<div class="mfn-body">Uppsala, Sweden – October 14, 2025 – As previously communicated Orexo will announce the Interim Report for the third quarter of 2025 on October 23 at 8 am CEST.At 2 pm the same day, analysts, investors and media are invited to a presentation where CEO Nikolaj Sørensen and CFO Fredrik Järrsten will present the latest developments. The company’s Chief Medical Officer, Edward Kim, will also participate to provide an update on the partnership with BARDA and the acceleration of the OX390 project. A Q&amp;A session will follow the presentation.The presentation will be broadcasted live and participants may access the event via live audiocast and teleconference through the following link: <a rel="noopener" href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Finvestorcaller.com%2Fevents%2Forexo%2Forexo-q3-report-2025&amp;data=05|02|Lena.Wange%40orexo.com|50adcc4f0fd84b2602ca08de019a3473|c2e2c5518fbf4c22b4b3101af7212583|1|0|638949959003162849|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=p%2BWQXAJt1y6zKfO5cMzbO0v3hbk7FBJ5SbXuqfLMqcs%3D&amp;reserved=0">https://investorcaller.com/events/orexo/orexo-q3-report-2025</a>Registration is required to participate. Once you have registered, you will receive the information needed to join the conference call. Participants will be provided with a dial-in number, a conference ID and a personal user ID – all of which are required to access the call. Please note that questions can be asked via the conference call or submitted through the audiocast.Prior to the event the presentation material will be available on the website under Investors/Report ArchiveFor further information contact: Lena Wange, IR &amp; Communications Director +46 18&nbsp;780 88 00 <a rel="noopener" href="mailto:ir@orexo.com">ir@orexo.com</a> &nbsp; About Orexo Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US. &nbsp; For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn,&nbsp;and YouTube.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/f3771f7f-7b41-436d-b529-494b6ce127f5/invitation-to-presentation-of-orexo-s-q3-2025-interim-report.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Orexo´s Q3 2025 Interim Report</a></div>